Stable and soluble antibodies inhibiting TNF alpha
US10100111B2 · kind B2 · utility
5Cited by
49References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 18, 2016 |
| Grant date | Oct 16, 2018 |
| Priority date | — |
| Expiry date | May 18, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNF-mediated disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.